Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Heather L. McFarland"'
Autor:
David J. Willock, Natasha M. Galea, Heather L. McFarland, Colin M. Hayman, Philip C. Bulman Page
Publikováno v:
Synlett. 2002:0583-0587
A synthesis of the tricyclic ring system of the daphnane and tigliane diterpenes, incorporating C-18 and the C-13 oxygen functionality found in phorbol and related compounds is described. The convergent synthesis utilizes an intramolecular Diels-Alde
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e975e6cb664530c77456da419f115de7
https://doi.org/10.1055/s-2002-22700
https://doi.org/10.1055/s-2002-22700
Autor:
Peter Ballard, Michael James, Daniel S. James, Peter D. Smith, Simon J. Brown, M. Raymond V. Finlay, Michael J. Waring, Paula Perkins, Andrew D. Campbell, Heather L. McFarland, David Perkins, Gordon S. Currie, Gillian M. Lamont, Graham Richmond, Matthew R. Box, David Whittaker, Mark J. Anderton, Richard A. Ward, Teresa Klinowska, Scott G. Lamont, Nicola Colclough, Stuart L. Wells, Darren Cross, Gail L. Wrigley, George B. Hill, Nathaniel G. Martin, Paul D. Kemmitt, Susan Ashton, Lorraine A. Hassall, Paul A. Bethel, Robert Hugh Bradbury, Sam Butterworth, Christopher G. Chorley, Martine J. Mellor, Matthew Grist, Jonathon P. Orme
Publikováno v:
Journal of medicinal chemistry. 57(20)
Epidermal growth factor receptor (EGFR) inhibitors have been used clinically in the treatment of non-small-cell lung cancer (NSCLC) patients harboring sensitizing (or activating) mutations for a number of years. Despite encouraging clinical efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d9360f89f601b2e2e19d1acdd90f2bb
https://pubmed.ncbi.nlm.nih.gov/25271963
https://pubmed.ncbi.nlm.nih.gov/25271963
Publikováno v:
Tetrahedron Letters. 38:6913-6916
A synthesis of the tetracyclic ring system of phorbol and other tigliane diterpenes has been achieved in six steps using an unusual intramolecular Diels-Alder reaction both as the key stereocontrolling process and to introduce a double bond appropria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::160026bcb9b488dfb7bed5be2aece33c
https://doi.org/10.1016/s0040-4039(97)01593-1
https://doi.org/10.1016/s0040-4039(97)01593-1
Autor:
Joanne Wilson, J. Matthew Wood, A. Nigel Brooks, Hill Kathryn Jane, Alfred A. Rabow, Graeme Walker, Andrew G. Thomason, Barry R. Hayter, Nicholas J. Howe, Stuart L. Wells, Glenn Hatter, David A. Jude, Sarah A. Loddick, Gorkhn Sharma-Singh, Scott G. Lamont, Heather L. McFarland, Dawn Trueman, Natalie Stratton, Zaieda Parveen, Nicola Broadbent, Carr Gregory Richard, David G. Acton, Robert Hugh Bradbury, Rhys D.O. Jones
Publikováno v:
Bioorganicmedicinal chemistry letters. 23(7)
Removal of the basic piperazine nitrogen atom, introduction of a solubilising end group and partial reduction of the triazolopyridazine moiety in the previously-described lead androgen receptor downregulator 6-[4-(4-cyanobenzyl)piperazin-1-yl]-3-(tri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f16196648857f254872da8adbf878d9
https://pubmed.ncbi.nlm.nih.gov/23466225
https://pubmed.ncbi.nlm.nih.gov/23466225
Publikováno v:
ChemInform. 28
A synthesis of the tetracyclic ring system of phorbol and other tigliane diterpenes has been achieved in six steps using an unusual intramolecular Diels-Alder reaction both as the key stereocontrolling process and to introduce a double bond appropria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::84bb881f144a1874c4479f0b471fec92
https://doi.org/10.1002/chin.199752201
https://doi.org/10.1002/chin.199752201
Autor:
Nicola Colclough, Mark J. Anderton, Martine J. Mellor, Rob H. Bradbury, Heather L. McFarland, Richard A. Ward, Sam Butterworth, M Ray V. Finlay, Darren Cross, Pete G. Ballard, Michael J. Waring, Susan Ashton
Publikováno v:
Cancer Research. 74:4744-4744
Small molecule inhibitors of the Epidermal Growth Factor Receptor (EGFR) tyrosine kinase such as gefitinib and erlotinib have been employed successfully in the treatment of non-small cell lung cancer (NSCLC) patients harboring an activating mutation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b497e25f1114f9701754b767510705fd
https://doi.org/10.1158/1538-7445.am2014-4744
https://doi.org/10.1158/1538-7445.am2014-4744
Autor:
Heather L. McFarland, Peter Ballard, Claudio Chuaqui, Susan Ashton, M. Raymond V. Finlay, Sam Butterworth, Martine J. Mellor, Darren Cross, Nicola Colclough, Rob H. Bradbury, Richard A. Ward, Mark J. Anderton, Michael J. Waring
Publikováno v:
Molecular Cancer Therapeutics. 12:B94-B94
Small molecule inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase such as gefitinib and erlotinib have been employed successfully in the treatment of non-small cell lung cancer (NSCLC) patients harboring an activating mutation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5bcabe801ac0cc9605b84173e10ac1bf
https://doi.org/10.1158/1535-7163.targ-13-b94
https://doi.org/10.1158/1535-7163.targ-13-b94
